title: Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.
abstract: Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-specific autoantibodies particularly against ribonucleoproteins. In the current paper, our aim is to summarize the latest findings supporting the association of type I IFN pathway with specific clinical manifestations in the setting of SLE providing insights on the potential use of type I IFN as a therapeutic target.
authors.affiliation: Department of Rheumatology, General Hospital of Athens G.Gennimatas, Mesogion St 154, 11527 Athens, Greece.
authors.forename: Theophanis P
authors.initials: TP
authors.lastname: Karageorgas
authors.forename: Dimitrios D
authors.initials: DD
authors.lastname: Tseronis
authors.forename: Clio P
authors.initials: CP
authors.lastname: Mavragani
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000097:blood*; D004195:Disease Models, Animal; D006801:Humans; D007370:Interferon Type I / Q000097:blood*; D008178:Lupus Erythematosus, Cutaneous / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D020945:Lupus Vasculitis, Central Nervous System / Q000097:blood*; D051379:Mice; D009393:Nephritis / Q000097:blood*; D010641:Phenotype; D012720:Severity of Illness Index; D015398:Signal Transduction
chemical_list: D007370:Interferon Type I